On Our Radar: Deals we are paying attention to for their impact on industry. Biotech firm Cullgen’s April 10 announcement that it had received a $16 million Series A financing aimed at advancing treatment of cancer and inflammatory and autoimmune diseases in a fresh way is another sign of the growing competition in this emerging […]


Know more, do more.

You'll get access to all of our original analysis, exclusive features, and more for just $9.

RELATED ARTICLESMORE FROM AUTHOR